Ftorafur® is widely used chemotherapeutic drug for the treatment of malignant tumors, particularly gastric, colorectal and breast cancer.
- Ftorafur® is synthesized in 1964 in the Institute of Organic Synthesis of the Latvian Academy of Sciences, and its discovery could be considered as an essential step in the development of chemotherapy.
- Experimental and clinical investigations of Ftorafur® took place in the USSR, Japan, USA and some European countries; since 1969 active co-operation took place with Japanese companies Taiho Pharmaceutical and Iskra.
- Ftorafur® is registered in Latvia, Lithuania, Hungary, Czech Republic, Russia and other CIS countries and it takes a significant place in the total sales volume of «Grindeks» as leading a export product.
- Ftorafur® active pharmaceutical ingredient (tegafur) is exported to Japan since 1972, though the final dosage form - 400 mg capsules - are sold in Baltic and CIS countries, Japan, as well as in the markets of several European countries.
- «Grindeks» is working on the further development of Ftorafur® in accordance with the latest developments in cancer treatments and the latest trends in global pharmaceuticals.
